Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
KRYS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$135.00 - $219.34
Previous CloseN/A
Volume44.50K
Average Volume (3M)304.90K
Market Cap
$4.03B
Enterprise Value$4.78B
Total Cash (Recent Filing)$1.96M
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)33.6
Beta0.83
Next Earnings
Aug 11, 2025EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding28,898,409
10 Day Avg. Volume239,055
30 Day Avg. Volume304,904
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda50.43
Forecast
1Y Price Target
$212.75Price Target Upside55.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Krystal Biotech News
PremiumCompany Announcements
Krystal Biotech Reports Strong Q1 2025 Results---
Bulls Say, Bears Say
Bulls Say
Financial StrengthThe company ended the quarter financially strong with $765.3 million in cash.
Growth PotentialPotential for Krystal to bounce back given historical trends and the potential contribution of launches in Europe and Japan.
Regulatory ApprovalsVYJUVEK set for first ex-U.S. launch with European Commission marketing approval, marking the first global launch since its approval and successful launch in the U.S.
Bears Say
Patient CompliancePatient compliance for Vyjuvek was 83%, a decline from the previous quarter due to various factors like complete sustained wound closure and plan switching.
Reimbursement SlowdownThe biggest update was the slowdown in reimbursement approvals which the company noted was related to the lower number of start forms received.
Revenue ChallengesVyjuvek revenue of $88.2M missed estimates and expectations due to compliance issues, slow new patient starts, and plan switching.
---
Ownership Overview
22.42% Insiders
33.93% Mutual Funds
0.06% Other Institutional Investors
18.92% Public Companies and
Individual Investors
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $135.00 and its highest was $219.34 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $4.03B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Aug 11, 2025 which is in 94 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on May 06, 2025. The company reported $1.2 earnings per share for the quarter, missing the consensus estimate of $1.427 by -$0.227.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.3.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 28,898,409 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.2 in its last earnings report, missing expectations of $1.427. Following the earnings report the stock price went down -14.061%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
---
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$212.75 (55.10% Upside)
$212.75 (55.10% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 19.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $106.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.13%
12-Months-Change
Fundamentals
Return on Equity
13.90%
Trailing 12-Months
Asset Growth
25.91%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
---
KRYS Company Deck
---
KRYS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as strong revenue growth, European expansion, and a robust clinical pipeline. However, challenges like the slowdown in reimbursement approvals and unpredictable patient pausing patterns were also discussed. The company's strong financial position and operational execution suggest a positive outlook, despite some operational challenges.Read More>---
KRYS Stock 12 Month Forecast
Average Price Target
$212.75
▲(55.10% Upside)
Technical Analysis
Cytokinetics
―
Sarepta Therapeutics
―
Blueprint Medicines
―
Axsome Therapeutics
―
Verona Pharma
―
---